~~<i id='871AFE6166'><strike id='871AFE6166'><tt id='871AFE6166'><pre id='871AFE6166'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：comprehensive 2025-08-12 06:44:23 - browse：299

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Abortion pill case raises question: who can sue the FDA?

Wikipedia

hotspot

focus

entertainment

knowledge

U.S.RepresentativeDonDavis(D-N.C.)WikimediaCommonsWASHINGTON—TwoRepublicanlawmakerswhointroducedlegi

WSS

Texas Medical Board asked to define abortion emergency exception

Primary care physicians play key roles in Alzheimer's management

A single Democrat is willing to weaken Medicare negotiation power

Adopting new red light myopia treatments may be short

Surgery pushed Ben Carson to fame

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

knowledge

entertainment

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

States should stop sabotaging methadone treatment reform

New air purifier tech could be key to improving indoor air quality

Adopting new red light myopia treatments may be short

Hepatitis C has a cure — but many Americans still lack access to it

Primary care physicians play key roles in Alzheimer's management

Walensky prepares to leave CDC — and Congress — behind

Why the world’s most expensive drug might be worth the price

Wildfire smoke exposes gaps in outdoor worker protections

Donor acceptance rates hint at racial, gender bias in heart transplants: study

hotspot

Patient advocates debate FDA's accelerated approval process

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Medicare Advantage plans can’t deny care with AI, CMS warns

Vertex Pharmaceuticals may move headquarters in Boston

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Readout LOUD podcast: mifepristone case, GLP

focus

focus

entertainment

knowledge